Palmieri Francesco, Lancellotti Francesco, Ferrara Francesco, Satyadas Thomas, Gobatti Davide, Abreu de Carvalho Luis Felipe, Gryspeerdt Filip, Conte Grazia, Mocchegiani Federico, Sampietro Roberto, Sileri Pierpaolo
Università Vita-Salute San Raffaele, Colorectal Surgery Unit, IRCCS Ospedale San raffaele, Milano, Italy.
Hepato-Pancreato-Biliary Unit, Manchester Royal Infirmary, Manchester, M139WL, UK.
ANZ J Surg. 2025 Jun;95(6):1187-1189. doi: 10.1111/ans.70027. Epub 2025 Feb 20.
Pancreas resection for metachronous colorectal cancer metastasis is episodic and the role of surgery in the management of these patients is still debated.
We recruited seven patients from three different centres and analyzed 30-day morbidity and mortality, oncological outcomes at 6 and 12 months.
There was no postoperative mortality. Complications occurred in two patients (28,6%). All patients completed at least a 12-months follow-up. At 6-month follow-up, only one patient had a recurrence. At 12-month follow-up, no patients died for disease recurrence and one more patient had a new recurrence.
Our series supports the feasibility and safety of pancreas resection in metastatic colorectal cancer suggesting that radical resection may improve the patient's prognosis.
针对异时性结直肠癌转移进行胰腺切除术是偶发性的,手术在这些患者管理中的作用仍存在争议。
我们从三个不同中心招募了7名患者,并分析了30天的发病率和死亡率、6个月和12个月时的肿瘤学结局。
无术后死亡病例。两名患者(28.6%)出现并发症。所有患者均完成了至少12个月的随访。在6个月随访时,只有一名患者复发。在12个月随访时,没有患者因疾病复发死亡,另有一名患者出现新的复发。
我们的系列研究支持在转移性结直肠癌中进行胰腺切除术的可行性和安全性,提示根治性切除可能改善患者预后。